Literature DB >> 6122510

High-dose dexamethasone for prevention of cis-platin-induced vomiting.

M S Aapro, D S Alberts.   

Abstract

Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting. Various reports have indicated benefits from steroids in this setting. We have tested a high-dose dexamethasone regimen with or without neuroleptics, which inhibits chemotherapy-induced vomiting in 50% of patients failing with prior antiemetics and in 71% of those who had not received prior antiemetics. This treatment was administered on an out-patient basis as it involved oral administration of the antiemetic. Neuroleptic therapy was not randomly assigned, but the results of this pilot study suggest that it did not enhance dexamethasone's efficacy. There were no significant side-effects due to the steroids. The antiemetic effectiveness of dexamethasone was retained through repeated courses of chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6122510     DOI: 10.1007/bf00258206

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  Double-blind evaluation of haloperidol for antiemetic activity.

Authors:  F J Tornetta
Journal:  Anesth Analg       Date:  1972 Nov-Dec       Impact factor: 5.108

2.  Prophylactic ibuprofen administration during pelvic irradiation.

Authors:  J A Stryker; L M Demers; R Mortel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979 Nov-Dec       Impact factor: 7.038

3.  A single dose of metoclopramide in the control of vomiting from cis-dichlorodiammineplatinum(II) in man.

Authors:  T Kahn; E G Elias; G R Mason
Journal:  Cancer Treat Rep       Date:  1978-07

4.  Steroid antiemesis may be harmful.

Authors:  M Haid
Journal:  N Engl J Med       Date:  1981-05-14       Impact factor: 91.245

5.  Possible mechanisms for the antitumor activity of platinum coordination complexes.

Authors:  B Rosenberg
Journal:  Cancer Chemother Rep       Date:  1975 May-Jun

6.  Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.

Authors:  H Ekert; K D Waters; I H Jurk; J Mobilia; P Loughnan
Journal:  Med J Aust       Date:  1979-12-15       Impact factor: 7.738

7.  Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.

Authors:  L E Orr; J F McKernan; B Bloome
Journal:  Arch Intern Med       Date:  1980-11

8.  Antagonism of cisplatin induced emesis in the dog.

Authors:  J A Gylys; K M Doran; J P Buyniski
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-01

9.  Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma.

Authors:  H S Bhakoo; N S Paolini; R J Milholland; R E Lopez; F Rosen
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

10.  Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.

Authors:  S Frytak; C G Moertel; J R O'Fallon; J Rubin; E T Creagan; M J O'Connell; A J Schutt; N W Schwartau
Journal:  Ann Intern Med       Date:  1979-12       Impact factor: 25.391

View more
  31 in total

1.  Effect of high dose of steroid on plateletcount in acute stage of dengue Fever with thrombocytopenia.

Authors:  K C Shashidhara; K A Sudharshan Murthy; H Basavana Gowdappa; Abhijith Bhograj
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms.

Authors:  C Peterson; T J Hursti; S Börjeson; E Avall-Lundqvist; M Fredrikson; C J Fürst; H Lomberg; G Steineck
Journal:  Support Care Cancer       Date:  1996-11       Impact factor: 3.603

3.  Alleviation of chemotherapy induced emesis by oral lorazepam and domperidone.

Authors:  P Warde; B Cantwell; J Fennelly; W Powderly; R Conroy
Journal:  Ir J Med Sci       Date:  1983-09       Impact factor: 1.568

Review 4.  Methodological issues in antiemetic studies.

Authors:  M Aapro
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

5.  Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting.

Authors:  S G Allan; M A Cornbleet; P S Warrington; I M Golland; R C Leonard; J N Smyth
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-06

6.  Does parenteral magnesium sulfate have an antiemetic effect during chemotherapy with cis-platinum?

Authors:  P E Ballmer; W H Reinhart
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.

Authors:  R A Joss; R L Galeazzi; K W Brunner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  The pharmacokinetics of single high doses of dexamethasone in cancer patients.

Authors:  M E Brady; G P Sartiano; S L Rosenblum; N E Zaglama; C T Bauguess
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment.

Authors:  H Bleiberg; S Van Belle; R Paridaens; G De Wasch; L Y Dirix; M Tjean
Journal:  Drugs       Date:  1992       Impact factor: 9.546

10.  Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.

Authors:  Katsunobu Oyama; Sachio Fushida; Masahide Kaji; Toshiya Takeda; Shinichi Kinami; Yasuo Hirono; Katsuhiro Yoshimoto; Kazuhisa Yabushita; Hisashi Hirosawa; Yuki Takai; Tatsuo Nakano; Hironobu Kimura; Toshiaki Yasui; Atsushi Tsuneda; Tomoya Tsukada; Jun Kinoshita; Takashi Fujimura; Tetsuo Ohta
Journal:  J Gastroenterol       Date:  2013-01-22       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.